The big business behind weight-loss drugs: Global market to hit $150 billion by 2035

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive big pharma's revenue for years to come. But they come with a hefty price tag, while some 50 to 70 percent of people taking GLP-1s suffer side effects. Charles Pellegrin asks Frederic Bizard, a health economist and professor at ESCP Business School, who has the most to gain from this pharma revolution.

Jul 4, 2025 - 00:00
182139
The big business behind weight-loss drugs: Global market to hit $150 billion by 2035
They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive big pharma's revenue for years to come. But they come with a hefty price tag, while some 50 to 70 percent of people taking GLP-1s suffer side effects. Charles Pellegrin asks Frederic Bizard, a health economist and professor at ESCP Business School, who has the most to gain from this pharma revolution.
Original Post >>    

This article has been sourced from various publicly available news platforms around the world. All intellectual property rights remain with the original publishers and authors. Unshared News does not claim ownership of the content and provides it solely for informational and educational purposes voluntarily. If you are the rightful owner and believe this content has been used improperly, please contact us for prompt removal or correction.